SummaryF‐18 fluorocholine [fluoromethyl‐dimethyl‐2‐hydroxyethyl‐ammonium (FCH)] is a choline analogue that shows great structural similarity to natural choline. The pathophysiological basis for the use of choline and its derivates for prostate cancer (PC) imaging are the elevation of choline levels and the up‐regulation of choline kinase activity in malignant cells. In order to allow rapid tumour growth, malignant cells are able to trap choline to produce phosphatidylcholine, part of the cellular membrane. As shown in recent studies, F‐18 choline PET and PET/CT might be a valuable tool in detecting the primary tumour in case of elevated prostate‐specific antigen (PSA) serum levels. However, data are not consistent, and further research is necessary before general recommendations concerning F‐18 choline PET and PET/CT can be given in this setting. Furthermore, some studies investigated the accuracy of F‐18 choline PET and PET/CT in detecting lymph node or bone metastases and local recurrences in case of PSA relapse in patients with a history of PC.
Imaging Decisions MRIVolume 13, Issue 1 p. 11-17 Imaging in COPD E. J. R. Van Beek, E. J. R. Van Beek Division of Physiologic Imaging, Department of Radiology, Carver College of Medicine, University of Iowa, Iowa City, IA, USASearch for more papers by this authorE. A. Hoffman, E. A. Hoffman Division of Physiologic Imaging, Department of Radiology, Carver College of Medicine, University of Iowa, Iowa City, IA, USASearch for more papers by this author E. J. R. Van Beek, E. J. R. Van Beek Division of Physiologic Imaging, Department of Radiology, Carver College of Medicine, University of Iowa, Iowa City, IA, USASearch for more papers by this authorE. A. Hoffman, E. A. Hoffman Division of Physiologic Imaging, Department of Radiology, Carver College of Medicine, University of Iowa, Iowa City, IA, USASearch for more papers by this author First published: 27 September 2009 https://doi.org/10.1111/j.1617-0830.2009.01130.xCitations: 5 Edwin JR van Beek, M.D. Ph.D. F.R.C.R.Department of Radiology, Carver College of Medicine, University of Iowa, C-751 GH, 200 Hawkins Drive, Iowa City, IA 52242-1077, USATel: 319 384 6133; Fax: 319 356 1503; E-mail: edwin-vanbeek@uiowa.edu Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Citing Literature Volume13, Issue1Spring 2009Pages 11-17 RelatedInformation
SummaryImaging is crucial for evaluating the presence and extent of prostate cancer. This review illustrates the role of imaging tools including ultrasound, computed tomography, magnetic resonance imaging, sentinel lymph adenectomy, positron emissions tomography and ohers for optimizing diagnosis and therapeutic concept in prostate cancer patients.
Summary Traditionally, myocardial perfusion imaging by CT has been hampered by limited detector size and stability of Hounsfield Units in moving cardiac acquisition modes. In the present article, we describe the technical principles of a novel, dynamic heart shuttle scan acquisition using a second generation dual source CT system (SOMATOM Definition Flash, Siemens Healthcare, Forchheim, Germany). With simultaneous injection of iodinated contrast agent, this protocol allows for sequential assessment of myocardial enhancement with reasonable radiation exposure of less than 10 mSv. We also present the case of a 69‐year‐old male patient who underwent dynamic CT‐based myocardial perfusion imaging to determine the hemodynamic relevance of a stenosis in the left anterior descending coronary artery.
SummaryIn prostate cancer, bone metastasis is related to a poor prognosis and is one of the major causes of morbidity and mortality. Detection of metastatic bone disease is particularly important in prostate cancer patients with high probability for distant metastases before embarking on radical prostatectomy or radiation therapy. The choice of imaging modalities that best depict the metastatic bony lesions may vary depending on different patterns of bone metastases. Bone scintigraphy has been used routinely in the evaluation of prostate cancer patients in the last decades. However, it suffers from adequate specificity. Single photon emission tomography (SPECT) increases the sensitivity and specificity of planar bone scanning especially for the evaluation of the spine. Recently, positron emission tomography (PET) using F‐18 Fluoride shows promising results in the detection of bone metastases especially in cancers with prominent osteoblasic pattern of bone metastases such as prostate cancer. This article reviews the value of conventional planar bone scanning, SPECT, SPECT/CT as well as F‐18 Fluoride PET/CT in the assessment of bone metastases in prostate cancer patients.
